Abstracts

HIGH PREVALENCE OF CNS DISSEMINATION WITH ASYMPTOMATIC CRYPTOCOCCAL ANTIGENEMIA

Screening for serum cryptococcal antigenemia (sCrAg) in advanced HIV is WHO recommended but with limited evidence to guide management of asymptomatic sCrAg+ individuals. We implemented a sCrAg screening program and estimated the prevalence of sCrAg antigenemia, central nervous system (CNS) dissemination, and mortality. HIV-infected individuals with CD4 counts ≤100cells/μl were enrolled at 20 outpatient clinics…

SERTRALINE AND HIGH-DOSE FLUCONAZOLE TREATMENT OF CRYPTOCOCCAL MENINGITIS IN TANZANIA

Cryptococcus neoformans is the leading cause of adult meningitis in sub-Saharan Africa. First-line antifungals are largely unavailable in this region. Sertraline has fungicidal activity against Cryptococcus, has synergy with fluconazole, and has shown promising results as an adjuvant for the treatment of cryptococcal meningitis. We prospectively enrolled 42 HIV-infected adults with cryptococcal meningitis at a…

MORTALITY DUE TO HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN BOTSWANA IN THE ART ERA

Cryptococcal meningitis (CM) is a leading cause of death in HIV-infected individuals in Africa. Case fatality rates of 20-35% with amphotericin-B based treatment have been reported in clinical trials conducted in Africa. These are not representative of standard medical care. We evaluated CM outcomes in a routine care setting utilizing centralized electronic medical records and…

CSF IMMUNE RESPONSES ASSOCIATED WITH DEPRESSION FOLLOWING CRYPTOCOCCAL MENINGITIS

Depression is common after AIDS-related central nervous system infections. Immunologic factors are involved in the development of depression, but few studies have evaluated CSF immune profiles. We assessed risk factors for depression, defined by a Center for Epidemiological Studies-Depression (CES-D) score of >=16, among those with cryptococcal meningitis enrolled in two clinical trials in Kampala,…

CLINICAL PERFORMANCE OF THE MP1P IMMUNOASSAY FOR RAPID DIAGNOSIS OF TALAROMYCOSIS

The gold standard to confirm Talaromyces marneffei infection (previously penicilliosis) is culture which can take up to 2 weeks. Diagnostic delay is associated with high mortality. Antigen detecting immunoassays offer rapid, specific and sensitive results, and have transformed management of other mycoses such as cryptococcosis. We describe the performance of the Mp1p immunoassay in a…

PREDICTING THE RISK OF DEATH IN HIV-ASSOCIATED TALAROMYCES MARNEFFEI INFECTION

Disseminated Talaromyces marneffei infection (formerly termed penicilliosis) is the third most common microbiologically confirmed opportunistic infection in Southeast Asia with mortality of up to 30% despite antifungal therapy. There are no clinical algorithms to predict treatment outcomes. We performed logistic regression and developed a simple risk prediction model for HIV-associated talaromycosis using data from a…

HOW WELL DO NEUROLOGIC SYMPTOMS IDENTIFY HIV-INFECTED INDIVIDUALS WITH NEUROSYPHILIS?

Current CDC guidelines recommend lumbar puncture in syphilis patients with signs or symptoms of neurologic disease. As part of a study of cerebrospinal fluid (CSF) abnormalities in syphilis, 410 HIV-infected individuals with untreated syphilis underwent lumbar puncture and a structured history that assessed the presence of new: headache, stiff neck, photophobia, vision loss, ocular inflammation,…

STOPPING SECONDARY TE PROPHYLAXIS IN SUPPRESSED PATIENTS WITH CD4 100-200 IS NOT SAFE

Current guidelines recommend that secondary Toxoplasma gondii prophylaxis can be safely discontinued in HIV-infected patients with suppressed viremia on antiretroviral therapy (ART) and a CD4 cell count >200 cells/mm3. Whether such a policy can be extended to patients with CD4 cell counts between 100-200 cells/mm3 is unknown. The Collaboration of Observational HIV Epidemiological Research in…